Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.33 |
| ▸ | WNT3A | P56704 | 2/20 | 0.33 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | PKLR | P30613 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL281983 | 0.69 | ALDH1A1 (0.40) | NPC1RAB9ATP53SMN1; SMN2CYP3A4 | |
| SCHEMBL2268770 | 0.59 | CYP3A4 (0.56) | NPC1RAB9APKMSMN1; SMN2CYP3A4 | |
| SCHEMBL2363085 | 0.59 | MAPT (0.35) | RAB9ATP53SMN1; SMN2CYP3A4MAOA | |
| SCHEMBL24434308 | 0.58 | CYP3A4 (0.56) | NPC1RAB9APKMSMN1; SMN2CYP3A4 | |
| SCHEMBL772701 | 0.56 | HSP90AA1 (0.51) | NPC1RAB9APKMSMN1; SMN2CYP3A4 | |
| SCHEMBL21667414 | 0.56 | SMN1; SMN2 (0.65) | RAB9ATP53SMN1; SMN2CYP3A4HPGD | |
| SCHEMBL3497076 | 0.55 | MAPT (0.75) | SMN1; SMN2CYP3A4HPGD | |
| SCHEMBL2783534 | 0.55 | MAPT (0.75) | SMN1; SMN2CYP3A4HPGD | |
| SCHEMBL14284022 | 0.55 | CYP3A4 (0.46) | PKMCYP3A4 | |
| SCHEMBL14284021 | 0.55 | CYP3A4 (0.46) | PKMSMN1; SMN2CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125072-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | NPC1 1791/4885RAB9A 757/4885PKM 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.